How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

9,770 results for

Cerebral Aneurysm

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

5301. Neural Substrates of Approach-Avoidance Conflict

) ( National Institute on Alcohol Abuse and Alcoholism (NIAAA) ) Study Details Study Description Go to Brief Summary: Background: - People who are dependent on alcohol drink even when they know something bad might happen. Researchers want to learn more about why they do this. Objectives: - To study brain response when a person plays a game in different threat conditions. Eligibility: Healthy right-handed adult heavy drinkers age 21 60 Healthy right-handed adult light drinkers age 21 60 Design: Participants (...) will be screened with medical history, physical exam, and blood and urine tests. They will have an EKG and psychiatric interview. Participants will have one or two clinic visits. Participants will be asked about their alcohol drinking. They will choose a snack and alcoholic beverage that they must drink in 5 minutes. After their breath alcohol content (BrAC) is zero, they will play a game in the MRI scanner. The scanner is a metal cylinder that takes pictures of the brain. Participants lie on a table

2014 Clinical Trials

5302. Intracerebral Hemorrhage Deferoxamine Trial

by Magdy Selim, Beth Israel Deaconess Medical Center: Brain hemorrhage Cerebral hemorrhage Bleeding in the brain Deferoxamine iDEF trial Additional relevant MeSH terms: Layout table for MeSH terms Hemorrhage Cerebral Hemorrhage Pathologic Processes Intracranial Hemorrhages Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Vascular Diseases Cardiovascular Diseases Deferoxamine Siderophores Iron Chelating Agents Chelating Agents Sequestering Agents Molecular (...) Center Study Details Study Description Go to Brief Summary: The investigators hypothesize that treatment with the iron chelator, Deferoxamine Mesylate, improves the outcome of patients with brain hemorrhage. The purpose of this study is to determine whether treatment with Deferoxamine Mesylate is of sufficient promise to improve outcome before pursuing a larger clinical trial to examine its effectiveness as a treatment for intracerebral hemorrhage. Condition or disease Intervention/treatment Phase

2014 Clinical Trials

5303. Tenecteplase Versus Alteplase in Ischemic Stroke Management (TALISMAN)

of intracranial hemorrhage on NECT Clinical suspicion of subarachnoid hemorrhage even with normal NECT NECT shows hypo-density greater than 1/3 cerebral hemisphere) History of intracranial hemorrhage/stroke Uncontrolled HTN: At time treatment begins SBP remains >185 mmHg or DBP remains >110 mmHg despite repeated measurements Known arteriovenous malformation, neoplasm, or aneurysm Witnessed seizure at stroke onset Acute bleeding tendencies Platelet count <100,000/mm3 Heparin received in prior 48 hours (...) : Tenecteplase Tenecteplase 0.25 mg/kg IV - Maximum 25 mg Other Name: TNKase Active Comparator: Alteplase Alteplase 0.9 mg/kg IV - Maximum dose: 90 mg Drug: Alteplase Alteplase 0.9 mg/kg IV - Maximum: 90 mg Other Names: Activase t-PA Outcome Measures Go to Primary Outcome Measures : Neurological outcome [ Time Frame: 90 days ] Measured by modified Rankin Scale score Secondary Outcome Measures : Symptomatic intracranial hemorrhage [ Time Frame: 24 hours ] Twenty-four hour brain CT scan showing intracranial

2014 Clinical Trials

5304. Ethnicity and Onset of Cardiovascular Disease: A CALIBER Study

Additional relevant MeSH terms: Layout table for MeSH terms Stroke Heart Failure Ischemia Infarction Cardiovascular Diseases Heart Diseases Myocardial Infarction Hemorrhage Aneurysm Angina Pectoris Heart Arrest Coronary Disease Coronary Artery Disease Myocardial Ischemia Aortic Aneurysm Peripheral Arterial Disease Peripheral Vascular Diseases Subarachnoid Hemorrhage Aortic Aneurysm, Abdominal Cerebral Hemorrhage Angina, Stable Death Ischemic Attack, Transient Death, Sudden, Cardiac Angina, Unstable (...) /Other) and first lifetime presentation of twelve different cardiovascular diseases. This information may help to predict the onset of cardiovascular diseases and inform disease prevention strategies. The hypothesis is that different ethnic groups have differing associations with the range of cardiovascular diseases studied. Condition or disease Abdominal Aortic Aneurysm Coronary Heart Disease Sudden Cardiac Death Intracerebral Haemorrhage Heart Failure Ischemic Stroke Myocardial Infarction Stroke

2014 Clinical Trials

5305. The Safety of High Dose Minocycline in the Patient Population Undergoing Carotid Revascularization

Criteria: Known hypersensitivity to tetracyclines Significant neurological deficit including but not limited to dense aphasia, hemi- or mono-paresis (motor strength equal or less than 3/5) or neglect. Baseline abnormalities on the MRI of the brain which would preclude the detection of new DWI or FLAIR changes. (e.g large areas of acute stroke, large areas of previous encephalomalacia, existing hardware such as aneurysm clips or coil masses etc.) Patients who are pregnant, breast-feeding, or lactating

2014 Clinical Trials

5306. Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With and Without Renal Impairment

of the first test) Evidence of haematuria either macroscopically detectable or microscopic on urinalysis (normal microscopic results after no more than one repeated test) Evidence of blood dyscrasia, haemorrhagic diathesis, severe thrombocytopenia, cerebrovascular haemorrhage, bleeding tendencies associated with active ulceration or overt bleeding of gastrointestinal, respiratory or genitourinary tract or any disease or condition with haemorrhagic tendencies (e.g. cerebral aneurysm, dissecting aorta (...) relevant Evidence of blood dyscrasia, haemorrhagic diathesis, severe thrombocytopenia, cerebrovascular haemorrhage, bleeding tendencies associated with active ulceration or overt bleeding of gastrointestinal, respiratory or genitourinary tract or any disease or condition with haemorrhagic tendencies (e.g. cerebral aneurysm, dissecting aorta, CNS trauma, retinopathy, nephrolithiasis) considered by the investigator or one of the co-investigators to be clinically relevant Recent or contemplated diagnostic

2014 Clinical Trials

5307. A Trial on Efficacy and Safety of Full Dose Tenecteplase Combined With Unfractionated Heparin (UFH) or Enoxaparin in Acute Myocardial Infarction (AMI) in the Prehospital Setting

: Composite endpoint: 30-day mortality or in-hospital reinfarction or in-hospital refractory ischemia or in-hospital intracranial hemorrhage (ICH) or in-hospital major bleedings (other than ICH) [ Time Frame: Up to 30 days after discharge from hospital ] Composite endpoints: 30-day mortality or in-hospital reinfarction or in-hospital refractory ischemia [ Time Frame: Up to 30 days after discharge from hospital ] Eligibility Criteria Go to Information from the National Library of Medicine Choosing (...) pericarditis and/or subacute bacterial endocarditis, acute pancreatitis, severe hepatic dysfunction, diabetic haemorrhagic retinopathy or other haemorrhagic ophthalmic conditions, active peptic ulceration, arterial aneurysm and known arterial/venous malformation, neoplasm with increased bleeding risk) Inability to follow protocol and comply with follow-up requirements Contacts and Locations Go to No Contacts or Locations Provided More Information Go to Layout table for additonal information Responsible

2014 Clinical Trials

5308. Relative Bioavailability of Single Doses of Dabigatran Etexilate in Healthy Volunteers

of: Hemorrhagic disorders or bleeding diathesis Occult blood in faeces or haematocryal Trauma or surgery within the last month or as long as an excessive risk of bleeding persisted after these events, or planned surgery during trial participation History of arteriovenous malformation or aneurysm History of gastroduodenal ulcer disease, gastrointestinal haemorrhage, and haemorrhoids History of intracranial, intraocular, spinal, retroperitoneal, or atraumatic intraarticular bleeding Use of drugs that may have

2014 Clinical Trials

5309. Whole Body Hyperthermia Registry Study

, for example peripheral vascular disease, deep vein thrombosis (DVT), or lymphedema. History of stroke, epilepsy or cerebral aneurisms Diabetes mellitus types I or II. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02174003 Locations Layout table

2014 Clinical Trials

5310. Optimal Laryngoscopic View to Enable GlideScope-assisted Tracheal Intubation

myelopathy, intracranial aneurysm or decreased intracranial compliance, Anatomic predictors of difficult GlideScope intubation (previous neck radiation or neck surgery), known very difficult direct laryngoscopy, inter-incisor mouth opening distance of < 3 cm (Cormack-Lehane Grade 3 or 4 laryngoscopy). Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided

2014 Clinical Trials

5311. Q-CAMP: Quantitative CArdiovascular Magnetic Resonance Imaging and Profiling of Atherosclerotic Lesions

: Subjects with any type of bio-implant activated by mechanical, electronic, or magnetic means (e.g. cochlear implants, pacemakers, neurostimulators, biostimulators, electronic infusion pumps, etc.). Subjects with any type of ferromagnetic bio-implant that could potentially be displaced or damaged, such as aneurysm clips, metallic skull plates, etc. Subjects with a history of kidney disease or dialysis that are unable to receive intravenous gadolinium contrast material. Female subjects. A urine pregnancy (...) to Share IPD: No Additional relevant MeSH terms: Layout table for MeSH terms Atherosclerosis Peripheral Arterial Disease Peripheral Vascular Diseases Vascular Diseases Carotid Artery Diseases Arteriosclerosis Arterial Occlusive Diseases Cardiovascular Diseases Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases

2014 Clinical Trials

5312. TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

Posted : May 20, 2014 Last Update Posted : March 7, 2019 Sponsor: National Cancer Institute (NCI) Information provided by (Responsible Party): National Cancer Institute (NCI) Study Details Study Description Go to Brief Summary: This phase I trial studies the side effects and best dose of raptor/rictor-mammalian target of rapamycin (mTOR) (TORC1/2) inhibitor MLN0128 when given in combination with bevacizumab in treating patients with glioblastoma, a type of brain tumor, or a solid tumor that has (...) with bevacizumab/VEGFR inhibitors is allowed in stage 1 for all participants, as well as stage 2 endometrial and ovarian cancer participants Stage 1 solid tumor and stage 2 endometrial and ovarian cancer participants with known central nervous system (CNS) metastatic lesions which are symptomatic and/or growing; patients previously treated for these conditions that are asymptomatic in the absence of corticosteroid therapy are allowed to enroll; brain metastasis must be stable for 1 month with verification

2014 Clinical Trials

5313. Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic I

be needed at any time during the study Use of hormone replacement therapy with oestrogen-based preparations for at least 1 month prior to screening and for the duration of the study Administration of antimicrobial agents within 10 days prior to Day 1 (Visit 2) Subjects with evidence of hepatocellular carcinoma, or who tested positive for serum alpha foeto protein > 5μg/l or suspected tumour based on ultrasonography examination, - Patients with history of stroke, intracranial aneurysm, neurosurgery (...) and skull traumatism within 4 weeks prior to screening History of intracranial, intraocular, spinal, retroperitoneal or atraumatic intraarticular bleeding Gastrointestinal hemorrhage within the past year Endoscopically documented gastro-duodenal ulcer disease in the previous 30 days Hemorrhagic disorder or bleeding diathesis Need for anticoagulant treatment for disorders Uncontrolled hypertension (systolic blood pressure (SBP) >180 mmHg and/or diastolic blood pressure (DBP) >100 mmHg) Contacts

2014 Clinical Trials

5314. Characterizing the Incretin Effect of Amino Acids and Defining GLP-1 Role on Skeletal Muscle

: i. Age 65-75 years ii. A body mass index (BMI) >18 and <28 kg/m2 Exclusion Criteria: For protocol 1: i. A BMI < 18 or > 28 kg·m2 ii. Active cardiovascular disease: uncontrolled hypertension (BP > 160/100), angina, heart failure (class III/IV), arrhythmia, right to left cardiac shunt or recent cardiac event iii. Cerebrovascular disease: previous stroke, aneurysm (large vessel or intracranial) iv. Respiratory disease including pulmonary hypertension, chronic obstructive pulmonary disease (COPD

2014 Clinical Trials

5315. Imaging Neuroinflammation in Epilepsy With Ferumoxytol MRI

the hospital stay History of central nervous system conditions other than seizure, including but not limited to history of brain surgeries, cerebral vascular accidents, encephalitis or meningitis, or diagnosis of brain tumors, cerebral aneurysms, multiple sclerosis or Alzheimer's disease. History of medical conditions that may influence iron metabolism, including but not limited to diagnosis of hemochromatosis, hyperbilirubinemia, hepatitis, cirrhosis or liver tumors, physical exam finding of jaundice (...) ): Barbara Jobst, Dartmouth-Hitchcock Medical Center Study Details Study Description Go to Brief Summary: The investigators plan to study inflammation in the brain (neuroinflammation) in human patients with epilepsy using a novel, non-invasive technique that has been proven successful in humans with other neuroinflammatory diseases. This technique uses ferumoxytol, a drug with minimal side effects that is FDA-approved for the treatment of iron deficiency anemia, as the contrast agent in magnetic

2014 Clinical Trials

5316. Role of Endothelin-1 in Flow-mediated Dilatation

for participation in the protocol or prevents giving informed consent Metabolic or endocrine disease Immunological diseases Renal or hepatic impairment Ischemic or obstructive heart disease Neoplastic disease Gastrointestinal disease Neurological disease , intracranial hypertension , seizure disorders Compulsive overeating , bulimia, anorexia Severe psychiatric illness Presence of a clinically significant abnormality in laboratory tests carried out at the inclusion visit . HBs Ag , HCV Ab , Ac HIV 1 or HIV 2 (...) : March 24, 2015 Last Verified: March 2015 Keywords provided by University Hospital, Rouen: Endothelin, endothelium, flow-mediated dilatation Additional relevant MeSH terms: Layout table for MeSH terms Aneurysm Dilatation, Pathologic Vascular Diseases Cardiovascular Diseases Pathological Conditions, Anatomical cyclo(Trp-Asp-Pro-Val-Leu) BQ 788 Antihypertensive Agents Endothelin Receptor Antagonists Molecular Mechanisms of Pharmacological Action Endothelin B Receptor Antagonists

2014 Clinical Trials

5317. Lumbar Fusion With The Icotec CF/PEEK Pedicle System In Combination With The Icotec CF/PEEK TLIF Cage ETurnâ„¢

growth factors. Growth factor enhanced grafts, cement or any other graft material are excluded. Adiposity, severe obesity (BMI > 35 kg/m2) Any contraindication for MRI scan including heart pacemaker, metallic foreign body (metal sliver) in the eye or brain, aneurysm clip in the brain, severe claustrophobia etc. Discitis, spondylodiscitis Acute or chronic infection, previous surgical site infection or severe defect of the osseous structures Open wounds Patient who takes immunosuppressive or long-term

2014 Clinical Trials

5318. Efficacy and Safety Study of rTMS for Upper Extremity Motor Function Recovery in Ischemic Stroke Patients

of stroke, cerebral vascular operation, seizure Pregnancy, Breastfeeding Patients with hemorrhagic stroke, traumatic brain injury Skin lesion in the stimulation site of scalp Metal implants in the body (cardiac pacemaker or aneurysm clip) Unable to have regular physical and occupational therapies on the affected hand Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact (...) : Other Study ID Numbers: E-1308-214-002 First Posted: March 7, 2014 Last Update Posted: January 26, 2018 Last Verified: January 2018 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: Undecided Keywords provided by Nam-Jong Paik, Seoul National University Bundang Hospital: Neuronal plasticity Transcranial magnetic stimulation Stroke Upper extremity Function Recovery Additional relevant MeSH terms: Layout table for MeSH terms Stroke Hemiplegia Cerebrovascular Disorders Brain

2014 Clinical Trials

5319. rTMS in Treatment Resistant Depression

: Be pregnant or lactating, planning to become pregnant within the next three months or sexually active and not using birth control. 2. Diagnosis with the following conditions (current unless otherwise stated): Have a neurological disorder, including a history of seizures, cerebrovascular disease, primary or secondary tumors in central nervous system, stroke, cerebral aneurysm or movement disorder or any lifetime history of loss of consciousness due to head injury. Any current Axis 1 psychotic disorder

2014 Clinical Trials

5320. Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From Acromegaly

pacemaker, brain (aneurysm) clip, nerve stimulators, electrodes, ear implants, post coronary by-pass graft (epicardial pace wires), penile implants, colored contact lenses, patch to deliver medications through the skin, coiled spring intrauterine device, vascular filter for blood clots, orthodontic braces, shunt- spinal or ventricular, any metal implants (rods, joints, plates, pins, screws, nails, or clips without MR-authorization), embolization coil, or any metal fragments or shrapnel in the body (...) Bone Diseases Musculoskeletal Diseases Hyperpituitarism Pituitary Diseases Hypothalamic Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Endocrine System Diseases

2014 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>